CHEST Physician
-
Advancing excellence: Why I pursued the CHEST CCAPP certification
The CCAPP certification demonstrates not only competence but also commitment to patients, teams, and the profession.
-
When oil infrastructure burns: What pulmonary clinicians should know
Recent conflict in the Middle East sheds light on oil fires as respiratory exposure events. Pulmonary clinicians need to be prepared to treat both acute and chronic symptoms from these exposures.
-
Navigating normotensive shock
Authors discuss the role normotensive shock plays in PE risk stratification according to new AHA guidelines on PE classification and management.
-
Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD
Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.
-
Triple therapy shows meaningful benefits in uncontrolled asthma
Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
-
Study supports early TB therapy to reduce sepsis mortality in HIV
The ATLAS team of researchers said that because typical sepsis treatment does not target TB, clinicians should consider immediate TB treatment for people with HIV-related sepsis.
-
Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis
Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.
-
Large, longitudinal study adds to evidence that links OSA to mental health disorder
Colin Huntley, MD, said the data help to confirm what many have seen in the clinic and suggest that patients may see mental health improvements if their sleep apnea is better managed.
-
Study finds triple combination modulator therapy reduces inflammation in CF
Valentino Bezzerri, PhD, discusses findings from a compassionate-use study examining the effects of elexacaftor/tezacaftor/ivacaftor on inflammation in patients with cystic fibrosis.
